Published on 18/12/2025
Labeling and Arabic Translation Requirements in MOHAP Submissions
Step 1: Understanding the MOHAP Regulatory Framework
The United Arab Emirates (UAE) has established a comprehensive framework for drug regulation. The Ministry of Health and Prevention (MOHAP) is responsible for the oversight of pharmaceuticals, which includes the approval processes for drug submissions. Understanding the MOHAP regulatory framework is essential for regulatory professionals in the pharmaceutical sector, as it dictates the requirements for labeling and documentation that must be adhered to during drug submissions.
Before commencing any submissions, it is critical to familiarize yourself with the relevant regulatory guidelines outlined by MOHAP. Primary regulatory documents include the UAE Federal Law No. 4 of 1983 on the Regulation of Pharmaceutical and Drug Products, and subsequent amendments. Additionally, the MOHAP guidelines on product registration and importation can provide detailed insights into the expectations for labeling and translation.
Regulatory professionals should regularly consult the official MOHAP website for any updates or changes to the regulatory requirements. Furthermore, attending training sessions and workshops offered by MOHAP or
Step 2: Preparing the Dossier Structure for Submission
The submission dossier to MOHAP must be meticulously prepared, adhering to the specified structure to ensure compliance with local requirements. The Common Technical Document (CTD) format is typically acceptable for submissions, consisting of five modules: Module 1 (Administrative Information and Prescribing Information), Module 2 (Summaries), Module 3 (Quality), Module 4 (Nonclinical Study Reports), and Module 5 (Clinical Study Reports).
Within Module 1, particular attention must be paid to labeled information, which must include product name, dosage form, strength, route of administration, and intended use. This module must contain detailed labeling translated into Arabic, as it is a requirement set forth by MOHAP. The Arabic translation needs to accurately reflect the content of the original English labels, ensuring consistency in meaning and terminology.
Quality documentation in Module 3 needs to include details regarding drug manufacturing processes, specifications, and stability data. Submission of Good Manufacturing Practice (GMP) certificates is mandatory. For Modules 4 and 5, comprehensive reports of nonclinical and clinical studies must be enclosed, adhering to the guidelines specified in the ICH-GCP and other relevant directives.
Step 3: Focus on Labeling Requirements for Submissions
Labeling is a critical component of drug regulatory affairs, providing essential information to healthcare professionals and patients. In the context of MOHAP submissions, there are strict mandates regarding the content and format of labeling. All labels must incorporate details such as active ingredients, usage instructions, contraindications, and adverse effects in both English and Arabic.
It is imperative to ensure that the labeling is not only informative but also compliant with local cultural and legal standards. Information such as dosage instructions and side effects must be clear and precise, minimizing the potential for confusion amongst the end-users. Additionally, specific graphical requirements may be stipulated, such as the inclusion of risk symbols or warnings, and these too must be accurately represented in the Arabic language.
MOHAP expects that all labeling should also accommodate any updates to pharmaceutical regulations, so regulatory teams must continuously monitor legal changes. Regular reviews of the label before submission are essential to ensure that the final version meets all regulatory specifications as outlined in the MOHAP guidelines.
Step 4: Translation Requirements for Arabic Language Compliance
The requirement for Arabic translations is one of the critical aspects of submitting dossiers to MOHAP. All labeling and associated documentation must be accurately translated into Arabic, ensuring that the meaning aligns with the original English text. The choice of a qualified, certified translator experienced in pharmaceutical language is paramount; inaccuracies in translation can result in regulatory delays or rejection of submissions.
Furthermore, translators must be aware of the relevant pharmaceutical terminology and ensure that cultural nuances are respected in the translation process. The translation should not merely be a word-for-word conversion, but must consider the context and convey the same meaning in Arabic as it does in the source language. Maintaining consistency in terminologies across various products under the same company is also crucial.
ISO standards relating to translation should be adhered to, and a review process should be documented to validate the accuracy of translations. This may involve back translations and validations by a second party to ensure there are no discrepancies. Thorough documentation of this translation process will greatly assist in the submission review by MOHAP.
Step 5: Submitting the Dossier to MOHAP
The submission process to MOHAP follows a series of important steps to ensure regulatory compliance. Once the dossier has been prepared and finalized, the next step involves submitting the application through MOHAP’s online system. It is crucial to create an account with MOHAP’s electronic portal for product registration, where users can submit their documentation and track the approval status.
Along with the complete dossier, include any additional forms or fees as stipulated by MOHAP regulations. The submission should also comprise any user guides or pertinent guidelines that enhance clarity around the product’s intended use and safety. Make sure that every piece of documentation submitted is up-to-date and accurately reflects the product’s current status.
Following submission, wait for an acknowledgment of receipt from MOHAP. This will outline the next steps in the review process. It is advisable to designate a team member responsible for communication with MOHAP during the review period to address any queries that may arise and facilitate a smoother review process. Patience is key, as the review may take several weeks depending on the complexity of the submission.
Step 6: Navigating the Review Process and Addressing Queries
After the dossier has been submitted, MOHAP will enter into a review phase where the documentation will be evaluated for compliance with regulatory standards. The review process may vary in duration, influenced by the completeness of the submission and any potential need for additional information. During this phase, it is not uncommon for MOHAP reviewers to issue queries to the submitting organization.
As such, it is essential to maintain open lines of communication with MOHAP throughout this period. The organization should prepare to respond promptly and thoroughly to any requests for further information. Establish a clear internal protocol to handle inquiries and responses, ensuring that all communication is documented and tracked. Each response should reference the specific query for clarity, and any required additional documentation should be clearly indicated.
Timely and accurate responses not only demonstrate professionalism but also align with regulatory expectations, potentially speeding up the review process. Additionally, make sure to review feedback from MOHAP carefully, as addressing concerns effectively can elevate the chances of approval and prevent further delays.
Step 7: Understanding Approval Timelines and Post-Approval Regulations
Once the review is complete and if the dossier meets all regulatory standards, MOHAP will approve the submission. Typical approval timelines may range from a few weeks to a few months based on various factors including the complexity of the product and the completeness of the initial submission.
After receiving approval, regulatory professionals must then focus on post-approval commitments. MOHAP mandates that any changes to product labeling, formulation, or manufacturing processes must be promptly reported and resubmitted for compliance checks. Regular pharmacovigilance is also required, ensuring that any adverse events associated with the drug are reported per the guidelines of the UAE and other international jurisdictions.
Regulatory teams must also organize periodic reviews of the product’s compliance with safety standards and regulations mandated by MOHAP. It is critical to stay abreast of any amendments to local laws that could impact the marketability and compliance of the product following its approval.
In conclusion, understanding the labeling and Arabic translation requirements in submissions to MOHAP is paramount for professionals engaged in pharmaceutical regulatory affairs. By following the outlined steps, organizations can streamline their submission processes, mitigate risks, and enhance compliance with local regulations, ultimately ensuring successful drug approvals in the UAE market.